iBio, Inc.

Contributing Author

Recent Articles by iBio, Inc.

Nov-12	iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update IBIO GlobeNewswire
Oct-30	iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance IBIO GlobeNewswire
Oct-23	iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference IBIO GlobeNewswire
Oct-21	iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek and PEGS Europe 2025 IBIO GlobeNewswire
Sep-05	iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update IBIO GlobeNewswire
Aug-25	iBio Announces Closing of $50 Million Public Offering IBIO GlobeNewswire
Aug-19	iBio Announces Pricing of $50 Million Public Offering IBIO GlobeNewswire
Aug-18	iBio Announces Proposed Public Offering IBIO GlobeNewswire
Jun-24	iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results IBIO GlobeNewswire
Jun-23	iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call IBIO GlobeNewswire
Jun-16	iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment IBIO GlobeNewswire
May-05	iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model IBIO GlobeNewswire
May-02	iBio Reports Fiscal Third Quarter 2025 Financial Results IBIO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.